Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study
Conclusions: This study demonstrates therapeutic equivalence of CT-P10 to RTX in previously untreated LTBFL. CT-P10 was well-tolerated and the safety profile including immunogenicity of CT P10 was comparable to that of RTX over 7 months.DisclosuresOgura: SymBio: Research Funding; Mundi Pharma: Consultancy; Celltrion: Consultancy, Research Funding; Takeda: Honoraria; Cellgene: Honoraria; MeijiSeika Pharma: Consultancy. Sancho: SERVIER: Honoraria; SANOFI: Honoraria; CELGENE: Honoraria; KERN FHARMA: Honoraria, Speakers Bureau; GILEAD: Honoraria, Research Funding; JANSSEN: Honoraria, Speakers Bureau; ROCHE: Honoraria, Speakers Bureau; MUNDIPHARMA: Honoraria. Lennard: Janssen: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Research Funding. Jurczak: European Medicines Agency: Consultancy; Astra Zeneca/Acerta: Consultancy, Research Funding; Sandoz-Novartis: Consultancy; Janssen: Consultancy, Research Funding; Gilead: Consultancy, Research Funding; Afimed: Research Funding; Bayer: Research Funding; Beigene: Research Funding; Celgene: Research Funding; Epizyme: Research Funding; Nordic Nanovector: Research Funding; Merck: Research Funding; Morphosys: Research Funding; Pharmacyclics: Research Funding; Servier: Research Funding; Roche: Research Funding; TG Therapeutics: Research Funding. Coiffier: CELGENE: Consultancy, Membership on an entity's Board of Directors or advis...
Source: Blood - Category: Hematology Authors: Ogura, M., Sancho, J. M., Cho, S.-G., Nakazawa, H., Suzumiya, J., Tumyan, G., Kim, J. S., Lennard, A., Mariz, J. M., Ilyin, N., Jurczak, W., Martinez, A. L., Samoilova, O., Zhavrid, E., Ruiz, E. Y., Trneny, M., Popplewell, L., Coiffier, B., Buske, C., Kim Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster I Source Type: research
More News: AstraZeneca | Chemotherapy | Employment | European Medicines Agency (EMA) | Genetics | Hepatitis | Hepatitis B | Lymphoma | Merck | Nanotechnology | Pharmaceuticals | Prednisone | Rituxan | Study